CHRISTINE PALECZNY: Open Payments
NPI 1316508112 · PROVIDENCE, RI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$644 in 38 payments from 9 companies in 2025. Trend: 2023 $689 · 2024 $1,332 · 2025 $644
Food & beverage: $644
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 25 | $369 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $71 |
| Otsuka America Pharmaceutical, Inc. | 2 | $54 |
| Axsome Therapeutics, Inc. | 2 | $51 |
| Janssen Pharmaceuticals, Inc | 2 | $30 |
| E.R. Squibb & Sons, L.L.C. | 1 | $20 |
| Neurocrine BioSciences, Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
Products named: VRAYLAR, CAPLYTA, REXULTI, Auvelity, SPRAVATO, COBENFY, INGREZZA, TRINTELLIX.
Industry payments across RI — which companies pay providers there.
